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ABSTRACT
HepSEQ is a repository for an extensive library of
public health and molecular data relating to hepatitis
B virus (HBV) infection collected from international
sources. It is hosted by the Centre for Infections,
Health Protection Agency (HPA), England, United
Kingdom. This repository has been developed as
a web-enabled, quality-controlled database to act
as a tool for surveillance, HBV case management
and for research. The web front-end for the data-
base system can be accessed from http://www.hpa-
bioinfodatabases.org.uk/hepatitis_open/main.php.
The format of the database system allows for com-
prehensive molecular, clinical and epidemiological
data to be deposited into a functional database, to
search and manipulate the stored data and to extract
and visualize the information on epidemiological,
virological, clinical, nucleotide sequence and muta-
tional aspects of HBV infection through web front-
end. Specific tools, built into the database, can be
utilized to analyse deposited data and provide
information on HBV genotype, identify mutations
withknownclinicalsignificance(e.g.vaccineescape,
precore and antiviral-resistant mutations) and carry
out sequence homology searches against other
deposited strains. Further mechanisms are also in
place to allow specific tailored searches of the
database to be undertaken.
INTRODUCTION
Viral hepatitis due to hepatitis B virus (HBV) is a major
worldwide public health concern leading to acute and chronic
liver disease including cirrhosis and hepatocellular carcinoma
(HCC) (1–4). It is currently estimated that over 2.5 billion
people are exposed and over 350 million people are chroni-
cally infected with the virus and that 1.2 million people
die annually from HBV-related disease (5–7). The prevalence
of HBV is known to be higher through Asia and the Middle
East, Africa, South America and the Mediterranean countries.
In these regions, transmission occurs mainly through vertical
and horizontal routes. In North America and Northern
Europe, where HBV prevalence is lower, sexual and intra-
venous drug use are the major modes of transmission (8,9).
There are few reliable predicators for the risk of deve-
loping serious consequences of HBV infection such as
host-related factors (gender, age at infection, degree of liver
damage at presentation and immune competence), environ-
mental factors (alcohol consumption, co-infection with
other viruses such as HIV and HCV and drug therapy) and
HBV-related factors (serological markers, viral load and
persistence of viral replication). HBV is currently classiﬁed
into eight genotypes (A–H) based on sequence divergence
over the entire genome exceeding 8% at the nucleotide
level (10–12). These major genotypes have a distinct geogra-
phical distribution (13,14). Additional variability in the
genome has been shown to arise as a result of the natural
emergence of strains which may have a selective advantage
during the course of chronic HBV infection in a patient,
e.g. precore mutants, deletions in the core gene, preS1 and
preS2 regions [for a review see (15)]. It is speculated that
these variants are driven by the immune system but it
currently remains unknown which, if any are clinically
signiﬁcant. Sequence evolution driven by external pressures
such as the introduction of immunization programmes and
more recently antiviral treatment has also given rise to a
number of mutations within the viral polymerase and
envelope regions [for a review see (16)].
Although in vitro studies have provided signiﬁcant informa-
tion into understanding the clinical signiﬁcance of sequence
changes, these data remain limited to a few speciﬁc mutations
(17,18). The development of databases containing detailed
genetic sequences of human pathogens provides a new point
of departure for the investigation of host–parasite relation-
ships. Using bioinformatics techniques it is possible to assess
pathogen relatedness and likely evolutionary pathways, and to
examine the pathways of sequence evolution of an agent in
response to a particular selection pressure such as antiviral
treatment. Furthermore, building a repository for such data
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HBV strains at regional, national and global levels, which is of
importance in an increasingly mobile population. Further-
more, such data provide a powerful tool in the public health
setting when investigating HBV transmission events and out-
breaks. Owing to these considerations there is an urgent need
to develop trusted databases to store reliable and curated data
on the public health aspects of HBV infections and to develop
appropriate methods and tools to extract and analyse the stored
data and report the information.
We present here HepSEQ (http://www.hpa-bioinfodatabases.
org.uk/hepatitis_open/main.php), a freely accessible web
resource on the public health aspects of HBV infection
with speciﬁc focus on epidemiological, virological, clinical,
nucleotide sequence and mutational aspects of HBV infec-
tion. HepSEQ is able to summarise and link large volumes
of data and present those in a visually intuitive format.
Moreover HepSEQ provides a resource to support detection
of variants in patients from different parts of the world, to
help monitor the dynamic of HBV variants during therapy
and potentially to contribute to re-design of diagnostic
assays.
HepSEQ
The architecture of the HepSEQ repository follows a three-
tier model. A front-end Apache web server serves content
to the client browsers. A middle dynamic content processing
and generation layer consists of PHP, CGI and PERL scripts
and specialized programs written in C (e.g. for sequence
alignment). Finally a backend database has both datasets
and relational database management system (RDBMS).
DATABASE
During the design and development of HepSEQ, initially all
the necessary requirements for a comprehensive public health
database on epidemiological, clinical and molecular markers
were identiﬁed through many discussions with the stakehold-
ers (clinicians and lab scientists) and then data modelling was
undertaken. After reviewing and improving the resultant
model several times, a data schema capable of catering to
diverse sources and formats of data was evolved and imple-
mented as a relational database using PostgreSQL open
source database management system on a Linux operating
system server. This schema consists of patient, sample,
gene and mutant tables, which have one to many relationships
between them. This schema enables multiple mutations to be
associated with a nucleotide sequence, multiple nucleotide
sequences to be associated with a sample and multiple sam-
ples to be associated with a patient.
DATA
The epidemiological, virological, clinical and nucleotide
sequence data were mainly collated from the participating
centres and manually checked before insertion to the data-
base. A set of standards called ‘Caldicott Standards’ are rec-
ommended by the Department of Health, England and govern
the use and transfer of patient-identiﬁable information from
National Health Service (NHS) organizations to other NHS
and non-NHS organizations (‘The Caldicott Report’ is avail-
able online at http://www.dh.gov.uk/assetRoot/04/06/84/04/
04068404.pdf and ‘Conﬁdentiality: NHS Code of Practice’
is available at http://www.dh.gov.uk/assetRoot/04/06/92/54/
04069254.pdf). Any patient data that do not follow Caldicott
Standards were excluded from the database. Ambiguities in
data were raised with the contributors and only stored in
the database once these were resolved.
WEB INTERFACE—USE AND APPLICATIONS
The web interface of HepSEQ has four major sections. The
ﬁrst of these sections contains the information pages accessed
through the top navigational bar. These pages display a sum-
mary of the current contents in the repository, an overview of
the HepSEQ system, and contact information. To facilitate
the dissemination of news, events of interest to the public
health community and latest publications on hepatitis, Really
Simple Syndication (RSS) feeds from different sources are
compiled and displayed on the News and Events page.
Updates relating to HepSEQ are also rendered as RSS feeds
and are available for download and display with a RSS news-
reader from the overview page. Information pages on clinical,
epidemiological and sequence display real-time data from the
current database records as pie and bar charts (Figure 1).
The second section in HepSEQ deals with data access and
submission. Users can either access all the records in a tabu-
lar form or access any detailed individual record by specify-
ing a patient, sample, gene or mutant identiﬁer. The search
page provides all the ﬁelds available in the database and dis-
tinct entries of those. Through this page any combination of
the speciﬁc ﬁelds in the database can be searched by user-
created unique queries and from the resultant tabular data,
individual detailed records can be viewed. Researchers inter-
ested in submitting data to HepSEQ can contact the curators
by email detailing the nature, type and amount of data they
wish to submit. After individually determining the best possi-
ble mechanism to submit data, the data will be bulk loaded
into a temporary table and manually curated. After reconcil-
ing any inconsistencies in the data with the submitter the
approved data will be migrated to the appropriate table.
The third section of the web interface provides graphical
tools to dynamically generate pie and bar charts from any
speciﬁed ﬁeld or a pair of ﬁelds. This tool can easily ﬁnd
the associations between different factors (e.g. outbreak and
genotype) and display those in a meaningful manner. Another
tool in this section integrates the Google map API with the
database and a speciﬁc parameter relating to the geographical
area can be viewed.
The last section in the web interface is the sequence ana-
lytical tools. Three tools are currently available, i.e. Sequence
Matcher, Genotyper and Mutation Marker.
The Sequence Matcher tool allows a user to input a DNA
sequence and search it against all the sequences deposited in
the HepSEQ. Protocols for identical matching as well as for
matching near-identical strain sequences are available. The
identical matching is implemented through the string match
functions of the programming language and is very fast.
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sequence matching algorithm from three available methods:
Smith–Waterman (19), Needleman–Wunsch (20) and BLAST
(21). The tabular format of the result is linked to individual
records as well as alignments. The beneﬁt of this tool is
that a user-input sequence can be linked to related sequences
and to potentially related cases.
The Genotyper tool assigns a genotype to a HBV sequence
provided by the user. The input sequence is pairwise matched
using the Needleman–Wunsch (20) algorithm against all the
reference sequences and highly scoring matches (>98%
sequence similarity) with statistical signiﬁcance are reported.
If the input sequence is not a recombinant sequence then an
unambiguous genotype can be predicted to the given
sequence. In this tool genotyping is done based on the
sequence similarity of surface/polymerase genes of HBV.
The reference sequences were assembled from the sequences
downloaded from GenBank and the sequences in the HepSEQ
system and validated using phylogenetic analysis. The list of
reference sequences is available as Supplementary Data.
The Mutation Marker tool allows sequences grouped by
different parameters (e.g. genotype) to be displayed as multi-
ple alignments, allowing sequence differences and gaps to be
visualized. This also annotates the alignment with clinically
important speciﬁc mutations related to vaccine escape or
antiviral resistance.
CONCLUSION AND FUTURE DIRECTIONS
The current release of HepSEQ is dedicated to be a compre-
hensive online resource for public health aspects of HBV
infection and offers a platform for further multi-factorial
analysis of HBV infection. In this current format the database
system is useful as an extensive library of HBV sequences
well annotated with clinical and epidemiological data.
The ﬁrst priority in future HepSEQ development is to
increase the number of data contributors and users and trying
to reach and receive data from almost all the centres and
laboratories involved in HBV infection studies. This will
make HepSEQ a truly global repository of HBV infection
data and a public health portal for HBV infection studies.
As the quality and consistency of the data availability is the
best indicator of any database system, in future, increased
focus will be towards data quality. In addition to the manual
curation currently automatic scripts also report on the quality
of the data. We would want to extend this to include the qual-
ity of the nucleotide sequences deposited in the system and to
report on the sequencing errors that might have occurred.
This has implications in assigning correct genotype to a
sequence and also in the subsequent multi-factorial analysis
of data. To achieve this although automated, web-based
approaches can be used to a certain extent, manual curation
remains the ‘gold standard’ until the acceptable parameters
for automated analysis are generally agreed.
Genotype–phenotype correlations are dependant on a
robust genotyping algorithm. There is a need to explore
approaches other than simple percentage sequence identities
between strains for genotype assignment as these can be unre-
liable where partial (rather than complete) genomic
sequences are available. Approaches such as integrating Posi-
tion Sensitive Scoring Matrices (PSSMs), recently applied to
HBV (22) with the current pairwise sequence comparisons
will be explored.
Figure 1. HepSEQ functionality. (A) Pie and bar charts displaying the categories of sequences in HepSEQ. (B) Search interface for HepSEQ. Sequence Matcher
(C) matches a user input sequence and produces a tabular format results page (D), from which detailed individual patient record (E) or the sequence record (F)
can be obtained.
Nucleic Acids Research, 2007, Vol. 35, Database issue D369There is also a need to present the sequence analytical tools
(genotyping and sequence alignment tools) as a webservice,
so that other web-based systems could utilize these services
without duplicating effort.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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